|
1
|
Beauchemin N and Arabzadeh A: Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 32:643–671. 2013.
|
|
2
|
Zid M and Drouin G: Gene conversions are under purifying selection in the carcinoembryonic antigen immunoglobulin gene families of primates. Genomics. 102:301–309. 2013.
|
|
3
|
Naghibalhossaini F, Yoder AD, Tobi M and Stanners CP: Evolution of a tumorigenic property conferred by glycophosphatidyl-inositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol Biol Cell. 18:1366–1374. 2007.
|
|
4
|
Wautier JL and Wautier MP: Old and new blood markers in human colorectal cancer. Int J Mol Sci. 23:129682022.
|
|
5
|
Obrink B: CEA adhesion molecules: Multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol. 9:616–626. 1997.
|
|
6
|
Kuespert K, Pils S and Hauck CR: CEACAMs: Their role in physiology and pathophysiology. Curr Opin Cell Biol. 18:565–571. 2006.
|
|
7
|
Voges M, Bachmann V, Naujoks J, Kopp K and Hauck CR: Extracellular IgC2 constant domains of CEACAMs mediate PI3K sensitivity during uptake of pathogens. PLoS One. 7:e399082012.
|
|
8
|
Kuijpers TW, Hoogerwerf M, van der Laan LJ, Nagel G, van der Schoot CE, Grunert F and Roos D: CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells. J Cell Biol. 118:457–466. 1992.
|
|
9
|
Frängsmyr L, Baranov V and Hammarström S: Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat. Tumour Biol. 20:277–292. 1999.
|
|
10
|
Oikawa S, Inuzuka C, Kuroki M, Arakawa F, Matsuoka Y, Kosaki G and Nakazato H: A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is mediated by N-domains. J Biol Chem. 266:7995–8001. 1991.
|
|
11
|
Yamanaka T, Kuroki M, Kinugasa T, Matsuo Y and Matsuoka Y: Preparation and characterization of two human carcinoembryonic antigen family proteins of neutrophils, CD66b and c, in silkworm larvae. Protein Expr Purif. 7:438–446. 1996.
|
|
12
|
Kuroki M, Abe H, Imakiirei T, Liao S, Uchida H, Yamauchi Y, Oikawa S and Kuroki M: Identification and comparison of residues critical for cell-adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J Leukoc Biol. 70:543–550. 2001.
|
|
13
|
Xu C and Ng DTW: Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol. 16:742–752. 2015.
|
|
14
|
Skubitz KM, Campbell KD and Skubitz AP: CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. J Leukoc Biol. 60:106–117. 1996.
|
|
15
|
Skubitz KM, Campbell KD and Skubitz AP: Synthetic peptides from the N-domains of CEACAMs activate neutrophils. J Pept Res. 58:515–526. 2001.
|
|
16
|
Oikawa S, Inuzuka C, Kuroki M, Matsuoka Y, Kosaki G and Nakazato H: Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: Homophilic and heterophilic adhesion. Biochem Biophys Res Commun. 164:39–45. 1989.
|
|
17
|
Bonsor DA, Günther S, Beadenkopf R, Beckett D and Sundberg EJ: Diverse oligomeric states of CEACAM IgV domains. Proc Natl Acad Sci USA. 112:13561–13566. 2015.
|
|
18
|
Huang R, Meng T, Zha Q, Cheng K, Zhou X, Zheng J, Zhang D and Liu R: The predicting roles of carcinoembryonic antigen and its underlying mechanism in the progression of coronavirus disease 2019. Crit Care. 25:2342021.
|
|
19
|
Pinkert J, Boehm HH, Trautwein M, Doecke WD, Wessel F, Ge Y, Gutierrez EM, Carretero R, Freiberg C, Gritzan U, et al: T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 11:20081102022.
|
|
20
|
Chiang WF, Cheng TM, Chang CC, Pan SH, Changou CA, Chang TH, Lee KH, Wu SY, Chen YF, Chuang KH, et al: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation. Oncogene. 37:116–127. 2018.
|
|
21
|
Friedrichson T and Kurzchalia TV: Microdomains of GPI-anchored proteins in living cells revealed by crosslinking. Nature. 394:802–805. 1998.
|
|
22
|
Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM and Stanners CP: GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol. 210:757–765. 2007.
|
|
23
|
Duxbury MS, Ito H, Ashley SW and Whang EE: c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. Biochem Biophys Res Commun. 317:133–141. 2004.
|
|
24
|
Cheng TM, Chang WJ, Chu HY, De Luca R, Pedersen JZ, Incerpi S, Li ZL, Shih YJ, Lin HY, Wang K, et al: Nano-strategies targeting the integrin αvβ3 network for cancer therapy. Cells. 10:16842021.
|
|
25
|
Blumenthal RD, Leon E, Hansen HJ and Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 7:22007.
|
|
26
|
Yan L, Wang Y, Wang ZZ, Rong YT, Chen LL, Li Q, Liu T, Chen YH, Li YD, Huang ZH and Peng J: Cell motility and spreading promoted by CEACAM6 through cyclin D1/CDK4 in human pancreatic carcinoma. Oncol Rep. 35:418–426. 2016.
|
|
27
|
Kurlinkus B, Ger M, Kaupinis A, Jasiunas E, Valius M and Sileikis A: CEACAM6's role as a chemoresistance and prognostic biomarker for pancreatic cancer: A comparison of CEACAM6's diagnostic and prognostic capabilities with those of CA19-9 and CEA. Life (Basel). 11:5422021.
|
|
28
|
Pandey R, Zhou M, Islam S, Chen B, Barker NK, Langlais P, Srivastava A, Luo M, Cooke LS, Weterings E and Mahadevan D: Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in pancreatic ductal adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Sci Rep. 9:183472019.
|
|
29
|
Ilantzis C, DeMarte L, Screaton RA and Stanners CP: Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia. 4:151–163. 2002.
|
|
30
|
Cao B, Wang P, Gu L and Liu J: Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma. Oncol Lett. 21:2492021.
|
|
31
|
Du H, Li Y, Sun R, Yuan Y, Sun S and Zhang Y: CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a. Thorac Cancer. 11:2473–2482. 2020.
|
|
32
|
Kim EY, Cha YJ, Jeong S and Chang YS: Overexpression of CEACAM6 activates Src-FAK signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas. Transl Oncol. 20:1014022022.
|
|
33
|
Son SM, Yun J, Lee SH, Han HS, Lim YH, Woo CG, Lee HC, Song HG, Gu YM, Lee HJ and Lee OJ: Therapeutic effect of pHLIP-mediated CEACAM6 gene silencing in lung adenocarcinoma. Sci Rep. 9:116072019.
|
|
34
|
Hong KP, Shin MH, Yoon S, Ji GY, Moon YR, Lee OJ, Choi SY, Lee YM, Koo JH, Lee HC, et al: Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity. Biomaterials. 67:32–41. 2015.
|
|
35
|
Liu Y, Chudgar N, Mastrogiacomo B, He D, Lankadasari MB, Bapat S, Jones GD, Sanchez-Vega F, Tan KS, Schultz N, et al: A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos. Sci Transl Med. 14:eabo10502022.
|
|
36
|
Li Y, Polyak D, Lamsam L, Connolly ID, Johnson E, Khoeur LK, Andersen S, Granucci M, Stanley G, Liu B, et al: Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases. NPJ Precis Oncol. 5:902021.
|
|
37
|
Wang X, Tang X, Gu J, Sun Z, Yang S, Mu Y, Guan M, Chen K, Liu W, Ruan H and Xu J: CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma. Cancer Med. 12:4521–4529. 2023.
|
|
38
|
Park W, Chawla A and O'Reilly EM: Pancreatic cancer: A review. JAMA. 326:851–862. 2021.
|
|
39
|
Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, Ashley SW, Maitra A, Redston M and Whang EE: CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg. 241:491–496. 2005.
|
|
40
|
Duxbury MS, Ito H, Ashley SW and Whang EE: CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun. 317:837–843. 2004.
|
|
41
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 23:465–473. 2004.
|
|
42
|
Long H, Li Q, Wang Y, Li Q, Liu T and Peng J: Effective combination gene therapy using CEACAM6-shRNA and the fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro. Exp Ther Med. 5:155–161. 2013.
|
|
43
|
Chen J, Li Q, An Y, Lv N, Xue X, Wei J, Jiang K, Wu J, Gao W, Qian Z, et al: CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Int J Oncol. 43:877–885. 2013.
|
|
44
|
Yuan L, Zhao J, Zhao S, Dong T, Dong R, Liu D, Ma E and Li Y: ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S. Chem Biol Interact. 353:1098112022.
|
|
45
|
Duxbury MS, Ito H, Ashley SW and Whang EE: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. J Biol Chem. 279:23176–23182. 2004.
|
|
46
|
Duxbury MS, Ito H, Benoit E, Ashley SW and Whang EE: CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer. 91:1384–1390. 2004.
|
|
47
|
Wang Y, Gangeswaran R, Zhao X, Wang P, Tysome J, Bhakta V, Yuan M, Chikkanna-Gowda CP, Jiang G, Gao D, et al: CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J Clin Invest. 119:1604–1615. 2009.
|
|
48
|
Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW and Whang EE: Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene. 23:5834–5842. 2004.
|
|
49
|
Schölzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B and Thompson J: Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 156:595–605. 2000.
|
|
50
|
Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger U, Herrmann R and Rochlitz C: Expression of CEACAM6 in resectable colorectal cancer: A factor of independent prognostic significance. J Clin Oncol. 21:3638–3646. 2003.
|
|
51
|
Yang T, Wang H, Li M, Yang L, Han Y, Liu C, Zhang B, Wu M, Wang G, Zhang Z, et al: CD151 promotes colorectal cancer progression by a crosstalk involving CEACAM6, LGR5 and Wnt signaling via TGFβ1. Int J Biol Sci. 17:848–860. 2021.
|
|
52
|
Wang J, Xiang H, Lu Y and Wu T: Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med. 47:552021.
|
|
53
|
Liu Y, Xia T, Jin C, Gu D, Yu J, Shi W, Zhang KE, Zhang L, Ye J and Li L: FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol Lett. 11:3693–3701. 2016.
|
|
54
|
Jin C, Liu Y, Zhu J, Xia T, Zhang B, Fei Y, Ma B, Ye J and Chen W: Recombinant Salmonella-based CEACAM6 and 4-1BBL vaccine enhances T-cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL and CEACAM6. Oncol Rep. 33:2837–2844. 2015.
|
|
55
|
Chi F, Chen L, Jin X, He G, Liu Z and Han S: CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway. Exp Cell Res. 412:1130352022.
|
|
56
|
Gong Z, Jia H, Xue L, Li D, Zeng X, Wei M, Liu Z, Tong MCF and Chen GG: The emerging role of transcription factor FOXP3 in thyroid cancer. Rev Endocr Metab Disord. 23:421–429. 2022.
|
|
57
|
Rodia MT, Ugolini G, Mattei G, Montroni I, Zattoni D, Ghignone F, Veronese G, Marisi G, Lauriola M, Strippoli P and Solmi R: Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget. 7:30295–30306. 2016.
|
|
58
|
Rodia MT, Solmi R, Pasini F, Nardi E, Mattei G, Ugolini G, Ricciardiello L, Strippoli P, Miglio R and Lauriola M: LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood markers for colorectal cancer-validation in a cohort of subjects with positive fecal immunochemical test result. Clin Colorectal Cancer. 17:e217–e228. 2018.
|
|
59
|
Ferlizza E, Solmi R, Miglio R, Nardi E, Mattei G, Sgarzi M and Lauriola M: Colorectal cancer screening: Assessment of CEACAM6, LGALS4, TSPAN8 and COL1A2 as blood markers in faecal immunochemical test negative subjects. J Adv Res. 24:99–107. 2020.
|
|
60
|
Ferlizza E, Solmi R, Sgarzi M, Ricciardiello L and Lauriola M: The roadmap of colorectal cancer screening. Cancers (Basel). 13:11012021.
|
|
61
|
Roy RK, Hoppe MM, Srivastava S, Samanta A, Sharma N, Tan KT, Yang H, Voon DC, Pang B, The M, et al: CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer. Oncotarget. 7:55290–55301. 2016.
|
|
62
|
Deng X, Liu P, Zhao Y and Wang Q: Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma. Genet Mol Res. 13:7686–7697. 2014.
|
|
63
|
Ru GQ, Han Y, Wang W, Chen Y, Wang HJ, Xu WJ, Ma J, Ye M, Chen X, He XL, et al: CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma. Oncotarget. 8:83673–83683. 2017.
|
|
64
|
An F, Zheng C, Zhang G, Zhou L, Wu Y, Hou Z, Zhou Z, Chen K and Zhan Q: Carcinoembryonic antigen related cell adhesion molecule 6 promotes carcinogenesis of gastric cancer and anti-CEACAM6 fluorescent probe can diagnose the precancerous lesions. Front Oncol. 11:6436692021.
|
|
65
|
Zhang Y, Zang M, Li J, Ji J, Zhang J, Liu X, Qu Y, Su L, Li C, Yu Y, et al: CEACAM6 promotes tumor migration, invasion, and metastasis in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 46:283–290. 2014.
|
|
66
|
Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu Z, Gu Q, Liu B and Yan M: CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway. PLoS One. 9:e1129082014.
|
|
67
|
Nieto MA, Sargent MG, Wilkinson DG and Cooke J: Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science. 264:835–839. 1994.
|
|
68
|
Ros MA, Sefton M and Nieto MA: Slug, a zinc finger gene previously implicated in the early patterning of the mesoderm and the neural crest, is also involved in chick limb development. Development. 124:1821–1829. 1997.
|
|
69
|
Cohen ME, Yin M, Paznekas WA, Schertzer M, Wood S and Jabs EW: Human SLUG gene organization, expression, and chromosome map location on 8q. Genomics. 51:468–471. 1998.
|
|
70
|
Savagner P: Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 23:912–923. 2001.
|
|
71
|
Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002.
|
|
72
|
Zang M, Zhang Y, Zhang B, Hu L, Li J, Fan Z, Wang H, Su L, Zhu Z, Li C, et al: CEACAM6 promotes tumor angiogenesis and vasculogenic mimicry in gastric cancer via FAK signaling. Biochim Biophys Acta. 1852:1020–1028. 2015.
|
|
73
|
Han SU, Kwak TH, Her KH, Cho YH, Choi C, Lee HJ, Hong S, Park YS, Kim YS, Kim TA and Kim SJ: CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. Oncogene. 27:675–683. 2008.
|
|
74
|
Chu C, Liu X, Zhao Z and Shi Z: Circ_0008035 promotes the progression of gastric cancer via the regulation of miR-1256/CEACAM6 axis. Cell Cycle. 21:1091–1102. 2022.
|
|
75
|
Chen SY, Zhang RG and Duan GC: Pathogenic mechanisms of the oncoprotein CagA in H. pylori-induced gastric cancer (Review). Oncol Rep. 36:3087–3094. 2016.
|
|
76
|
Xia R, Zhang B, Wang X and Jia Q: Pathogenic interactions between Helicobacter pylori adhesion protein HopQ and human cell surface adhesion molecules CEACAMs in gastric epithelial cells. Iran J Basic Med Sci. 22:710–715. 2019.
|
|
77
|
Behrens IK, Busch B, Ishikawa-Ankerhold H, Palamides P, Shively JE, Stanners C, Chan C, Leung N, Gray-Owen S and Haas R: The HopQ-CEACAM interaction controls CagA translocation, phosphorylation, and phagocytosis of Helicobacter pylori in neutrophils. mBio. 11:e03256–19. 2020.
|
|
78
|
Toh J, Hoppe MM, Thakur T, Yang H, Tan KT, Pang B, Ho S, Roy R, Ho KY, Yeoh KG, et al: Profiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination. BMJ Open Gastroenterol. 7:e0004522020.
|
|
79
|
Zhao ZS, Li L, Wang HJ and Wang YY: Expression and prognostic significance of CEACAM6, ITGB1, and CYR61 in peripheral blood of patients with gastric cancer. J Surg Oncol. 104:525–529. 2011.
|
|
80
|
Tsang JY, Kwok YK, Chan KW, Ni YB, Chow WN, Lau KF, Shao MM, Chan SK, Tan PH and Tse GM: Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. Breast Cancer Res Treat. 142:311–322. 2013.
|
|
81
|
Balk-Møller E, Kim J, Hopkinson B, Timmermans-Wielenga V, Petersen OW and Villadsen R: A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: Luminal and HER2-enriched. Am J Pathol. 184:1198–1208. 2014.
|
|
82
|
Zhao SJ, Zhao HD, Li J, Zhang H, Gao DT and Wang Q: CD151 promotes breast cancer metastasis by activating TGF-β1/Smad signaling pathway. Eur Rev Med Pharmacol Sci. 22:7314–7322. 2018.
|
|
83
|
Wang SE: The functional crosstalk between HER2 tyrosine kinase and TGF-β signaling in breast cancer malignancy. J Signal Transduct. 2011:8042362011.
|
|
84
|
Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I and Speirs V: Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol. 31:557–565. 2007.
|
|
85
|
Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL and Jordan VC: Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer. 44:1770–1779. 2008.
|
|
86
|
Khoury T, Kanehira K, Wang D, Ademuyiwa F, Mojica W, Cheney R, Morrison C, Conroy J, Nowak N and Liu S: Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis. Mod Pathol. 23:1364–1378. 2010.
|
|
87
|
Ihnen M, Kilic E, Köhler N, Löning T, Witzel I, Hagel C, Höller S, Kersten JF, Müller V, Jänicke F, et al: Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin. J Clin Pathol. 64:146–152. 2011.
|
|
88
|
Koh EY, You JE, Jung SH and Kim PH: Biological functions and identification of novel biomarker expressed on the surface of breast cancer-derived cancer stem cells via proteomic analysis. Mol Cells. 43:384–396. 2020.
|
|
89
|
Gong L and Liu X, Jiao L, Yang X, Lemoff A and Liu X: CK2-mediated phosphorylation of SUZ12 promotes PRC2 function by stabilizing enzyme active site. Nat Commun. 13:67812022.
|
|
90
|
Ieta K, Tanaka F, Utsunomiya T, Kuwano H and Mori M: CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer. 95:532–540. 2006.
|
|
91
|
Rose JB, Correa-Gallego C, Li Y, Nelson J, Alseidi A, Helton WS, Allen PJ, D'Angelica MI, DeMatteo RP, Fong Y, et al: The role of biliary carcinoembryonic antigen-related cellular adhesion molecule 6 (CEACAM6) as a biomarker in cholangiocarcinoma. PLoS One. 11:e01501952016.
|
|
92
|
Tian C, Zhang B and Ge C: Effect of CEACAM6 silencing on the biological behavior of human gallbladder cancer cells. Oncol Lett. 20:2677–2688. 2020.
|
|
93
|
Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ and Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol. 109:234–239. 2008.
|
|
94
|
du Manoir S, Delpech H, Orsetti B, Jacot W, Pirot N, Noel J, Colombo PE, Sardet C and Theillet C: In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. J Pathol. 257:367–378. 2022.
|
|
95
|
Ye Y, Wang J, Liang F, Song P, Yan X, Wu S, Huang X and Han P: Identification of key genes for HNSCC from public databases using bioinformatics analysis. Cancer Cell Int. 21:5492021.
|
|
96
|
Bednarek K, Kostrzewska-Poczekaj M, Szaumkessel M, Kiwerska K, Paczkowska J, Byzia E, Ustaszewski A, Janiszewska J, Bartochowska A, Grenman R, et al: Downregulation of CEACAM6 gene expression in laryngeal squamous cell carcinoma is an effect of DNA hypermethylation and correlates with disease progression. Am J Cancer Res. 8:1249–1261. 2018.
|
|
97
|
Cameron S, de Long LM, Hazar-Rethinam M, Topkas E, Endo-Munoz L, Cumming A, Gannon O, Guminski A and Saunders N: Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis. Mol Cancer. 11:742012.
|
|
98
|
Wang Z, Luo C, Wang H, Yan X, Liu W and Meng Z: CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial-mesenchymal transition in osteosarcoma cells. Onco Targets Ther. 11:3159–3166. 2018.
|
|
99
|
Lasa A, Serrano E, Carricondo M, Carnicer MJ, Brunet S, Badell I, Sierra J, Aventín A and Nomdedéu JF: High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias. Ann Hematol. 87:205–211. 2008.
|
|
100
|
Kanderová V, Hrusák O and Kalina T: Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells. Exp Hematol. 38:653–660.e1. 2010.
|
|
101
|
Steiner N, Hajek R, Nachbaur D, Borjan B, Sevcikova S, Göbel G and Gunsilius E: Levels of CEACAM6 in peripheral blood are elevated in patients with plasma cell disorders: A potential new diagnostic marker and a new therapeutic target? Dis Markers. 2019:18060342019.
|
|
102
|
Zhu R, Ge J, Ma J and Zheng J: Carcinoembryonic antigen related cell adhesion molecule 6 promotes the proliferation and migration of renal cancer cells through the ERK/AKT signaling pathway. Transl Androl Urol. 8:457–466. 2019.
|
|
103
|
Igami K, Uchiumi T, Shiota M, Ueda S, Tsukahara S, Akimoto M, Eto M and Kang D: Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients. Cancer Sci. 113:3120–3133. 2022.
|
|
104
|
Wu SJ, Arundhathi A, Wang HC, Chen CY, Cheng TM, Yuan SF and Wang YM: Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti-CEACAM6 antibodies. Transl Oncol. 14:1010572021.
|
|
105
|
Youssef A, Haskali MB and Gorringe KL: The protein landscape of mucinous ovarian cancer: Towards a theranostic. Cancers (Basel). 13:55962021.
|
|
106
|
Han ZW, Lyv ZW, Cui B, Wang YY, Cheng JT, Zhang Y, Cai WQ, Zhou Y, Ma ZW, Wang XW, et al: The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs. 38:1888–1898. 2020.
|
|
107
|
Johnson B and Mahadevan D: Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies. Clin Cancer Drugs. 2:100–111. 2015.
|
|
108
|
Burgos M, Cavero-Redondo I, Álvarez-Bueno C, Galán-Moya EM, Pandiella A, Amir E and Ocaña A: Prognostic value of the immune target CEACAM6 in cancer: A meta-analysis. Ther Adv Med Oncol. 14:175883592110726212022.
|
|
109
|
Schäfer D, Tomiuk S, Küster LN, Rawashdeh WA, Henze J, Tischler-Höhle G, Agorku DJ, Brauner J, Linnartz C, Lock D, et al: Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun. 12:14532021.
|
|
110
|
Witzens-Harig M, Hose D, Jünger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, et al: Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 121:4493–4503. 2013.
|
|
111
|
Jin C, Duan X, Liu Y, Zhu J, Zhang K, Zhang Y, Xia T, Fei Y and Ye J: T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model. Oncol Lett. 13:3753–3759. 2017.
|
|
112
|
Schettini F, Barbao P, Brasó-Maristany F, Galván P, Martínez D, Paré L, De Placido S, Prat A and Guedan S: Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open. 6:1001022021.
|
|
113
|
Zeligs KP, Morelli MP, David JM, Neuman M, Hernandez L, Hewitt S, Ozaki M, Osei-Tutu A, Anderson D, Andresson T, et al: Evaluation of the anti-tumor activity of the humanized monoclonal antibody NEO-201 in preclinical models of ovarian cancer. Front Oncol. 10:8052020.
|
|
114
|
Cheng TM, Murad YM, Chang CC, Yang MC, Baral TN, Cowan A, Tseng SH, Wong A, Mackenzie R, Shieh DB and Zhang J: Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells. Eur J Cancer. 50:713–721. 2014.
|
|
115
|
Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, et al: Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 69:1933–1940. 2009.
|
|
116
|
Niu G, Murad YM, Gao H, Hu S, Guo N, Jacobson O, Nguyen TD, Zhang J and Chen X: Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release. 161:18–24. 2012.
|
|
117
|
Lee H, Jang Y, Park S, Jang H, Park EJ, Kim HJ and Kim H: Development and evaluation of a CEACAM6-targeting theranostic nanomedicine for photoacoustic-based diagnosis and chemotherapy of metastatic cancer. Theranostics. 8:4247–4261. 2018.
|
|
118
|
Zou J, Chen S, Li Y, Zeng L, Lian G, Li J, Chen S, Huang K and Chen Y: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Nanoscale. 12:4473–4490. 2020.
|
|
119
|
Ordoñez C, Screaton RA, Ilantzis C and Stanners CP: Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 60:3419–3424. 2000.
|
|
120
|
Chuang PC, Lu CW, Tsai CC, Tseng SH and Su WH: MicroRNA-128 confers anti-endothelial adhesion and anti-migration properties to counteract highly metastatic cervical cancer cells' migration in a parallel-plate flow chamber. Int J Mol Sci. 22:2152020.
|
|
121
|
Blumenthal RD, Hansen HJ and Goldenberg DM: Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 65:8809–8817. 2005.
|
